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Introduction
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with personal or familial history of psoriasis. PsA is characterized by heterogeneous clinical presentation, with possible axial and/or peripheral joint involvement, enthesitis and dactylitis [1] .
In PsA, as well as in other forms of inflammatory arthritis, an increased cardiovascular risk (CV) has been observed. Increased prevalence of traditional CV risk factors, chronic inflammation and potential adverse effects of drugs, especially corticosteroids and nonsteroidal antiinflammatory drugs (NSAIDs), contribute to CV comorbidity in PsA [2] [3] [4] . Notably, chronic inflammation can affect global CV risk on multiple points of view. The expression of a more atherogenic lipid profile, the forced reduction of physical activity, and the increased production of cytokines involved in plaque formation, such as interleukin (IL)-1, IL-17, and tumor necrosis factor (TNF)-alpha, seem to boost CV risk of patients [2] . Accelerated atherosclerosis seems to play a pivotal role predisposing patients with PsA to the development of CV and cerebrovascular events [5] .
Therefore, the identification of high CV risk patients with psoriatic arthritis is particularly important, in order to implement preventive strategies, like lifestyle changes and pharmacological interventions. A large number of CV risk algorithms have been proposed over time [6] . The performance of algorithms for calculating CV risk in patients with another inflammatory, like rheumatoid arthritis (RA), is a largely debated subject. In particular, Arts and coworkers [7] assessed the performance of four CV risk algorithms in establishing the risk of fatal and non-fatal CV events in European patients with RA. The results show that different scores (Framingham, SCORE, Reynold's Risk Score, QRISK2) tend to underestimate CV risk in patients with RA; the risk observed exceeds that predicted; the different scores appear slightly calibrated for RA patients [8] . In addition, Ernst and coauthors demonstrated that the Framingham Risk Score (FRS) underestimates CV risk in patients with psoriatic arthritis [9] .
Recently, the European League Against Rheumatism (EULAR) recommended to adapt the general population risk algorithms with a multiplication by the factor of 1.5 in patients with rheumatoid arthritis and other inflammatory arthritis, except for QRISK2 which is characterized by a multiplication factor intrinsic to the algorithm for rheumatoid arthritis [10] .
Only a few data evaluate the performance of different algorithms, both original and adapted according to EULAR indication, in predicting the actual CV risk in PsA. In this study, the performance of FRS, Systematic Coronary Risk Evaluation (SCORE), QRISK2, Reynolds risk score (RRS), and the Italian Progetto CUORE individual score is evaluated in a bicentric cohort of patients with psoriatic arthritis from Rome and Neaples (Italy).
Methods
A retrospective analysis of prospective collected data from PsA cohort of Unit of Immunorheumatology, Università Campus Bio-Medico di Roma, and Unit of Rheumatology, University of Neaples "Federico II", has been made in November 2017. Patients without a personal history of CV disease (CVD) at baseline (November 2007) were consecutively included in this study.
At baseline, all the patients fulfilled the Classification Criteria for Psoriatic Arthritis (CASPAR) [11] .
Ethics committee of Università Campus Bio-Medico di Roma approved the study, which complied with the Declaration of Helsinki.
Baseline characteristics extracted from the cohort database: were age (years), gender (male/ female), weight (kg), height (cm) The primary outcome was the first CV event (fatal and non-fatal), as report by electronic patient files. CV events were considered: sudden cardiac death, coronary artery diseases (CAD) (stable and unstable angina pectoris, myocardial infarction), cerebral vascular accident (CVA), transient ischemic attack (TIA), peripheral artery disease (PAD) and heart failure.
The 10-year general FRS for CVD [12] , QRISK2 [13] , CUORE [14] and RRS [15, 16] were calculated using already published algorithms. SCORE risk charts for low risk countries were used [17] . The items included in each CV risk algorithm are reported in Table 1 . Cut-off values that mark the difference between low-to-intermediate risk and intermediate-to-high risk were 10% and 20% respectively, except for SCORE in which cut-off values were 1% and 5%.
At baseline, data from medical record were used to calculate individual risk for CV within 10 years for all five algorithms. The discriminatory ability of all five algorithms was evaluated using the area under the receiver operating characteristic (ROC) curve, which is similar to the concordance-statistic (c-statistic). Calibration was assessed by comparing the agreement between observed and predicted number of CV events in groups stratified in deciles, sextiles, or septiles of the predicted risk, as appropriate, using Hosmer-Lemeshow (HL) test. Fisher's exact test has been used for analysis of contingency table, while Mann-Whitney test has been used to compare ranks. The sample size, calculated setting a type I error to 0.05, the test power to 0.8, the AUC of the adapted test to 0.7, was 143 patients [18] . All statistical analysis was performed using STATA V.14.
Results
Data from 155 patients (1550 patient-years) were analyzed. All the patients were Caucasic and lived in Center or South of Italy. During follow-up, 21 patients had a CV event (1.35 events per 100 patient/years): 8 cases of myocardial infarction or unstable angina pectoris, 3 cases of stable angina pectoris, 2 cases of TIA, 4 cases of PAD, 4 cases of HF. No fatal events were reported. The primary outcome was adjusted to fit each CV risk algorithm, leaving 21, 15, 11, 17, and 15 CV events for Framingham, QRISK2, RRS, SCORE, and CUORE, respectively. As the RRS is not applicable to patients with diabetes or younger than 45 years, these patients (n = 58) were excluded, and only 97 patients were included in the analysis of RRS. Patients characteristics are summarized in Table 2 . 0.57795 to 0.85862) for SCORE, CUORE, FRS, QRISK2, and RRS respectively were found ( Fig  1A-1E) . (Fig 2A-2E) .
Overall, a discrepancy between predicted risk and observed CV events was found (Fig 3A-3E) .
CUORE score underestimated CV risk in middle and top deciles and HL test demonstrated poor model fit (p = 0.045); the multiplication by the factor of 1.5 did not improve the performance (HL test p = 0.045). QRISK2 and QRISK2-RA underestimated CV risk in middle deciles and overestimated CV risk in top deciles, and HL test did not demonstrate poor model fit (p = 0.162). CV risk predicted by FRS and FRS Ã 1.5 was lower than observed CV events in every decile, but HL test did not yield a poor model fit (p = 0.26 for FRS and p = 0.259 for FRS Ã 1.5). SCORE and SCORE Ã 1.5 tended to underestimate CV risk in every sextile considered and HL test provided poor model fit (p<0.5). HL test yield poor model fit also for RRS and RRS Ã 1.5 as well (p<0.05). Sensitivity and specificity of the 10% and 20% cut-off points for CV risk for FRS, QRISK2, CUORE, and RRS and of the 1% and 5% cut-off points for CV risk for SCORE are reported in Table 3 .
Among patients with CV event, 17.6% was at "low risk" and 52.9% at "low-intermediate risk" according to SCORE, 80% was at "low risk" and 93.3% was at "low-intermediate risk" according to CUORE, 76.2% was at "low risk" and 95.2% was at "low-intermediate risk" according to FRS, 20% was at "low risk" and 60% was at "low-intermediate risk" according to QRISK2, 81.8% was at "low risk" and 90.9% was at "low-intermediate risk" according to RRS, 5.9% was at "low risk" and 52.9% was at "low-intermediate risk" according to SCORE Ã 1.5, 66.7% was at "low risk" and 86.7% was at "low-intermediate risk" according to CUORE Ã 1.5, 61.9% was at "low risk" and 85.7% was at "low-intermediate risk" according to FRS Ã 1.5, 46.7% was at "low risk" and 80% was at "low-intermediate risk" according to QRISK2-RA, and 45.4% was at "low risk" and 81.8% was at "low-intermediate risk" according to RRS Ã 1.5.
Discussion
The prevention of CV events in general population still remains a challenge. In patients with inflammatory arthritis, an increased burden of CV comorbidity and mortality is well established [10] . Despite in psoriatic arthritis an increased CV risk has been demonstrated [19] , little is known about CV risk algorithm in these patients. Overall, the five algorithms evaluated in this study underestimated CV risk. A relatively good discrimination between patients with or without CV events has been demonstrated, with areas under the ROC curves between 0.7183 for RSS and 0.8660 for QRISK2, and calibration of all five algorithms was poor to moderate. In 2015/2016, EULAR suggested to adapt CV risk algorithms by a factor of 1.5 (or to include the independent risk factor RA in QRISK2) in all the patients with RA and virtually other inflammatory arthritis, such as PsA. Notably, in this study the adaptation suggested by EULAR did not increase the discriminative ability and calibration of none of the five algorithms under consideration. Despite the discriminative ability in patients with PsA is comparable to general population, the five algorithms performed less well in terms of calibration [12- 17]. Particularly, a poor model fit with a significant different distribution of observed events compared to predicted ones has been demonstrated for CUORE, SCORE, and RSS, but not for FRS and QRISK2. Most of CV events reported in this study occurred in patients at "low risk" or at "low-intermediate risk". In general population and in patients with PsA as well, people at "low risk" or "low-intermediate risk" are less likely to receive any preventive treatment. Consequently, according to the results of our study, it seems crucial to redefine cut-off values for low and intermediate CV risk in patients PsA. Data reported in the present study demonstrate that, among all the evaluated models, QRISK2 and QRISK2-RA show the best discriminative ability and calibration in Caucasic patients with PsA from Center and South of Italy. These Moreover, Shen and coworkers tested the performance of several CV risk scores, including FRS, QRISK2, SCORE, 10-year atherosclerotic cardiovascular disease risk algorithm (ASCVD) from the American College of Cardiology and the American Heart Association, and the EULAR-recommended modified versions by 1.5 multiplication factor in discriminating subclinical atherosclerosis in PsA patients. Also in this case, results showed that all CV risk scores underestimated the subclinical atherosclerosis risk. Further, EULAR-recommended 05 , suggesting a good model fit, but it cannot be excluded a low power of the test for these algorithms probably due to small sample size.
In conclusion, this study extensively studied five CV risk algorithms in an Italian population of patients with PsA. Overall, these algorithms and their cut-off for low and intermediate risk tend to provide less accurate prediction of CV risk in patients with PsA compared to general population. Underestimation of CV risk in PsA patients could lead to insufficient treatment of CV risk factors. Prospective and larger studies are required in order to improve CV risk prediction in PsA patients, redefining cut-off values of already available algorithms, adding more biomarkers and disease-related CV risk factors in prediction models, and providing PsA-specific CV risk algorithms. 
